ANDAORALCAPSULE
Approved
Mar 1969
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
HUMATIN (paromomycin sulfate) by Pfizer is clinical pharmacology the in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. First approved in 1969.
Drug data last refreshed 21h ago
$0.0BPart D
Mechanism of Action
CLINICAL PHARMACOLOGY The in-vitro and in-vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Pfizer
NEW YORK, NY
Worked on HUMATIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.